Cargando…
The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells
Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Whether TH1902 impacts the chemoresistance phenotype...
Autores principales: | Demeule, Michel, Charfi, Cyndia, Currie, Jean-Christophe, Zgheib, Alain, Danalache, Bogdan Alexandru, Béliveau, Richard, Marsolais, Christian, Annabi, Borhane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503230/ https://www.ncbi.nlm.nih.gov/pubmed/36145658 http://dx.doi.org/10.3390/pharmaceutics14091910 |
Ejemplares similares
-
TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer
por: Demeule, Michel, et al.
Publicado: (2021) -
The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers
por: Currie, Jean-Christophe, et al.
Publicado: (2022) -
New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells
por: Charfi, Cyndia, et al.
Publicado: (2021) -
A Role for the Cavin-3/Matrix Metalloproteinase-9 Signaling Axis in the Regulation of PMA-Activated Human HT1080 Fibrosarcoma Cell Neoplastic Phenotype
por: Toufaily, Chirine, et al.
Publicado: (2014) -
Cavin-2 Functions as a Suppressive Regulator in TNF-induced Mesenchymal Stromal Cell Inflammation and Angiogenic Phenotypes
por: Annabi, Bayader, et al.
Publicado: (2017)